Safety Update: ALTITUDE ‘unboost’

by Kazeem Olalekan MRPharmS Early result from the ALiskiren Trial In Type 2 diabetes Using cardiovascular and renal Disease Endpoints (ALTITUDE) study has shown that: study patients were unlikely to benefit from aliskiren; and an increased incidence of non-fatal strokes, renal complications (including acute renal failure), hyperkalaemia and hypotension in patients randomised to the aliskiren […]